Emmanuèle Délot

Emmanuèle Délot

Auto-generated profile, based on publicly available information

Emmanuèle Délot

Institute for Clinical and Translational Science, University of California, Irvine, Irvine, CA.

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2001 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
BJBrian K. Jordan
Brian K. Jordan
MMMansoor Mohammed
Mansoor Mohammed
SCSaunders T. Ching
Saunders T. Ching
EDEmmanuèle Délot
Emmanuèle Délot
XCXiao-Ning Chen
Xiao-Ning Chen
EVEric Vilain
Eric Vilain

27 May 2012 in Nature Genetics
Verified
Journal Article
Open access
PDF file
VAValerie A Arboleda
Valerie A Arboleda
HLHane Lee
Hane Lee
RPRahul Parnaik
Rahul Parnaik
AFAlice Fleming
Alice Fleming
ABAbhik Banerjee
Abhik Banerjee
EVEric Vilain
Eric Vilain
Eric Vilain and colleagues identify missense mutations in the imprinted gene CDKN1C, encoding the p57KIP2 cyclin dependent kinase inhibitor, in individuals with IMAGe syndrome. IMAGe syndrome is a developmental disorder characterized by intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita and genital anomalies. IMAGe syndrome (intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita and genital anomalies) is an undergrowth developmental disorder with life-threatening consequences1. An identity-by-descent analysis in a family with IMAGe syndrome2 identified a 17.2-Mb locus on chromosome 11p15 that segregated in the affected family members. Targeted exon array capture of the disease locus, followed by high-throughput genomic sequencing and validation by dideoxy sequencing, identified missense mutations in the imprinted gene CDKN1C (also known as P57KIP2) in two familial and four unrelated patients. A familial analysis showed an imprinted mode of inheritance in which only maternal transmission of the mutation resulted in IMAGe syndrome. CDKN1C inhibits cell-cycle progression3, and we found that targeted expression of IMAGe-associated CDKN1C mutations in Drosophila caused severe eye growth defects compared to wild-type CDKN1C, suggesting a gain-of-function mechanism. All IMAGe-associated mutations clustered in the PCNA-binding domain of CDKN1C and resulted in loss of PCNA binding, distinguishing them from the mutations of CDKN1C that cause Beckwith-Wiedemann syndrome, an overgrowth syndrome4.

1 February 2015 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
RBRuth M. Baxter
Ruth M. Baxter
VAValerie A. Arboleda
Valerie A. Arboleda
HLHane Lee
Hane Lee
HBHayk Barseghyan
Hayk Barseghyan
MAMargaret P. Adam
Margaret P. Adam
EVEric Vilain
Eric Vilain
Context: Disorders of sex development (DSD) are clinical conditions where there is a discrepancy between the chromosomal sex and the phenotypic (gonadal or genital) sex of an individual. Such conditions can be stressful for patients and their families and have historically been difficult to diagnose, especially at the genetic level. In particular, for cases of 46,XY gonadal dysgenesis, once variants in SRY and NR5A1 have been ruled out, there are few other single gene tests available. Objective: We used exome sequencing followed by analysis with a list of all known human DSD-associated genes to investigate the underlying genetic etiology of 46,XY DSD patients who had not previously received a genetic diagnosis. Design: Samples were either submitted to the research laboratory or submitted as clinical samples to the UCLA Clinical Genomic Center. Sequencing data were filtered using a list of genes known to be involved in DSD. Results: We were able to identify a likely genetic diagnosis in more than a third of cases, including 22.5% with a pathogenic finding, an additional 12.5% with likely pathogenic findings, and 15% with variants of unknown clinical significance. Conclusions: Early identification of the genetic cause of a DSD will in many cases streamline and direct the clinical management of the patient, with more focused endocrine and imaging studies and better-informed surgical decisions. Exome sequencing proved an efficient method toward such a goal in 46,XY DSD patients.

25 October 2017 in Genome Medicine
Verified
Journal Article
Open access
PDF file
HBHayk Barseghyan
Hayk Barseghyan
WTWilson Tang
Wilson Tang
RWRichard T. Wang
Richard T. Wang
MAMiguel Almalvez
Miguel Almalvez
ESEva Segura
Eva Segura
EVEric Vilain
Eric Vilain
Massively parallel DNA sequencing, such as exome sequencing, has become a routine clinical procedure to identify pathogenic variants responsible for a patient’s phenotype. Exome sequencing has the capability of reliably identifying inherited and de novo single-nucleotide variants, small insertions, and deletions. However, due to the use of 100–300-bp fragment reads, this platform is not well powered to sensitively identify moderate to large structural variants (SV), such as insertions, deletions, inversions, and translocations. To overcome these limitations, we used next-generation mapping (NGM) to image high molecular weight double-stranded DNA molecules (megabase size) with fluorescent tags in nanochannel arrays for de novo genome assembly. We investigated the capacity of this NGM platform to identify pathogenic SV in a series of patients diagnosed with Duchenne muscular dystrophy (DMD), due to large deletions, insertion, and inversion involving the DMD gene. We identified deletion, duplication, and inversion breakpoints within DMD. The sizes of deletions were in the range of 45–250 Kbp, whereas the one identified insertion was approximately 13 Kbp in size. This method refined the location of the break points within introns for cases with deletions compared to current polymerase chain reaction (PCR)-based clinical techniques. Heterozygous SV were detected in the known carrier mothers of the DMD patients, demonstrating the ability of the method to ascertain carrier status for large SV. The method was also able to identify a 5.1-Mbp inversion involving the DMD gene, previously identified by RNA sequencing. We showed the ability of NGM technology to detect pathogenic structural variants otherwise missed by PCR-based techniques or chromosomal microarrays. NGM is poised to become a new tool in the clinical genetic diagnostic strategy and research due to its ability to sensitively identify large genomic variations.

3 June 2021 in Nature Reviews Genetics
Verified
Journal Article
Closed access
PDF file
EDEmmanuèle C. Délot
Emmanuèle C. Délot
EVEric Vilain
Eric Vilain

14 November 2007 in Developmental Neurobiology
Verified
Journal Article
Closed access
PDF file
XCXuqi Chen
Xuqi Chen
RWRebecca Watkins
Rebecca Watkins
EDEmmanuele Delot
Emmanuele Delot
RRRamune Reliene
Ramune Reliene
RSRobert H. Schiestl
Robert H. Schiestl
AAArthur P. Arnold
Arthur P. Arnold